Tags

Type your tag names separated by a space and hit enter

Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson's Disease.
Int J Mol Sci. 2021 Aug 18; 22(16)IJ

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the Substantia Nigra pars compacta, leading to classical PD motor symptoms. Current therapies are purely symptomatic and do not modify disease progression. Cannabidiol (CBD), one of the main phytocannabinoids identified in Cannabis Sativa, which exhibits a large spectrum of therapeutic properties, including anti-inflammatory and antioxidant effects, suggesting its potential as disease-modifying agent for PD. The aim of this study was to evaluate the effects of chronic treatment with CBD (10 mg/kg, i.p.) on PD-associated neurodegenerative and neuroinflammatory processes, and motor deficits in the 6-hydroxydopamine model. Moreover, we investigated the potential mechanisms by which CBD exerted its effects in this model. CBD-treated animals showed a reduction of nigrostriatal degeneration accompanied by a damping of the neuroinflammatory response and an improvement of motor performance. In particular, CBD exhibits a preferential action on astrocytes and activates the astrocytic transient receptor potential vanilloid 1 (TRPV1), thus, enhancing the endogenous neuroprotective response of ciliary neurotrophic factor (CNTF). These results overall support the potential therapeutic utility of CBD in PD, as both neuroprotective and symptomatic agent.

Authors+Show Affiliations

Unit of Cellular and Molecular Neurobiology, IRCCS Mondino Foundation, 27100 Pavia, Italy.Unit of Cellular and Molecular Neurobiology, IRCCS Mondino Foundation, 27100 Pavia, Italy.Unit of Cellular and Molecular Neurobiology, IRCCS Mondino Foundation, 27100 Pavia, Italy.Unit of Cellular and Molecular Neurobiology, IRCCS Mondino Foundation, 27100 Pavia, Italy.Unit of Cellular and Molecular Neurobiology, IRCCS Mondino Foundation, 27100 Pavia, Italy.Linnea SA, CH-6595 Riazzino, TI (CH), Switzerland.Unit of Cellular and Molecular Neurobiology, IRCCS Mondino Foundation, 27100 Pavia, Italy. Linnea SA, CH-6595 Riazzino, TI (CH), Switzerland. Department of Brain and Behavioral Sciences, University of Pavia, 27100 Pavia, Italy.Unit of Cellular and Molecular Neurobiology, IRCCS Mondino Foundation, 27100 Pavia, Italy.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

34445626

Citation

Giuliano, Claudio, et al. "Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson's Disease." International Journal of Molecular Sciences, vol. 22, no. 16, 2021.
Giuliano C, Francavilla M, Ongari G, et al. Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson's Disease. Int J Mol Sci. 2021;22(16).
Giuliano, C., Francavilla, M., Ongari, G., Petese, A., Ghezzi, C., Rossini, N., Blandini, F., & Cerri, S. (2021). Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson's Disease. International Journal of Molecular Sciences, 22(16). https://doi.org/10.3390/ijms22168920
Giuliano C, et al. Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson's Disease. Int J Mol Sci. 2021 Aug 18;22(16) PubMed PMID: 34445626.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson's Disease. AU - Giuliano,Claudio, AU - Francavilla,Miriam, AU - Ongari,Gerardo, AU - Petese,Alessandro, AU - Ghezzi,Cristina, AU - Rossini,Nora, AU - Blandini,Fabio, AU - Cerri,Silvia, Y1 - 2021/08/18/ PY - 2021/07/04/received PY - 2021/08/14/revised PY - 2021/08/16/accepted PY - 2021/8/27/entrez PY - 2021/8/28/pubmed PY - 2021/9/21/medline KW - 6-hydroxydopamine KW - cannabidiol KW - ciliary neurotrophic factor KW - neuroinflammation KW - phytocannabinoids KW - transient receptor potential vanilloid 1 JF - International journal of molecular sciences JO - Int J Mol Sci VL - 22 IS - 16 N2 - Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the Substantia Nigra pars compacta, leading to classical PD motor symptoms. Current therapies are purely symptomatic and do not modify disease progression. Cannabidiol (CBD), one of the main phytocannabinoids identified in Cannabis Sativa, which exhibits a large spectrum of therapeutic properties, including anti-inflammatory and antioxidant effects, suggesting its potential as disease-modifying agent for PD. The aim of this study was to evaluate the effects of chronic treatment with CBD (10 mg/kg, i.p.) on PD-associated neurodegenerative and neuroinflammatory processes, and motor deficits in the 6-hydroxydopamine model. Moreover, we investigated the potential mechanisms by which CBD exerted its effects in this model. CBD-treated animals showed a reduction of nigrostriatal degeneration accompanied by a damping of the neuroinflammatory response and an improvement of motor performance. In particular, CBD exhibits a preferential action on astrocytes and activates the astrocytic transient receptor potential vanilloid 1 (TRPV1), thus, enhancing the endogenous neuroprotective response of ciliary neurotrophic factor (CNTF). These results overall support the potential therapeutic utility of CBD in PD, as both neuroprotective and symptomatic agent. SN - 1422-0067 UR - https://www.unboundmedicine.com/medline/citation/34445626/Neuroprotective_and_Symptomatic_Effects_of_Cannabidiol_in_an_Animal_Model_of_Parkinson's_Disease_ L2 - https://www.mdpi.com/resolver?pii=ijms22168920 DB - PRIME DP - Unbound Medicine ER -